Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969477586> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W2969477586 endingPage "B15" @default.
- W2969477586 startingPage "B15" @default.
- W2969477586 abstract "We assessed the rate of isotretinoin therapy interruptions and terminations due to lipid, liver function, and hematologic lab abnormalities in patients with acne who had hypercholesterolemia (HC), hypertriglyceridemia (TG), elevated alanine aminotransferase (ALT), leukopenia, or thrombocytopenia prior to initiating isotretinoin, a drug associated with these abnormalities. We reviewed records for patients with acne and baseline HC, TG, elevated ALT, leukopenia, or thrombocytopenia who started isotretinoin from January 1, 2008 to June 1, 2016 at Brigham & Women’s Hospital and Massachusetts General Hospital. Therapy interruptions and terminations due to continued lab abnormalities were assessed. Abnormalities were defined by the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 grading system. 141 patients with a total of 153 baseline abnormalities started isotretinoin. The most severe baseline abnormality was a grade 1 in 130 of 141 patients (92.2%), grade 2 in 7 (5.0%), grade 3 in 1 (0.7%) and grade 4 in 3 (2.1%). The most common abnormalities were HC (57.5%), leukopenia (19.6%) and TG (15.7%). Over the course of treatment, abnormal labs led to interruptions in 5 of 141 patients (3.5%) and terminations in 6 patients (4.2%). All interruptions were due to elevated ALT, and none resulted in termination. 9 of 11 total treatment modifications (81.8%) were the result of lab abnormalities not present at baseline. The low rate of treatment modifications due to lab abnormalities during isotretinoin therapy for patients with baseline lab abnormalities suggests physicians should not be deterred from initiating treatment in these patients. The majority of abnormal labs resulting in modifications were not present at baseline and no interruptions led to terminations, supporting literature that abnormalities are often transient. Further studies determining optimum screening protocols and confirming these findings with larger sample sizes of patients with high-grade abnormalities are warranted." @default.
- W2969477586 created "2019-08-29" @default.
- W2969477586 creator A5016027668 @default.
- W2969477586 creator A5053193999 @default.
- W2969477586 creator A5083722360 @default.
- W2969477586 date "2019-09-01" @default.
- W2969477586 modified "2023-10-02" @default.
- W2969477586 title "LB1103 Interruptions and terminations of isotretinoin treatment in patients with acne and lab abnormalities" @default.
- W2969477586 doi "https://doi.org/10.1016/j.jid.2019.06.068" @default.
- W2969477586 hasPublicationYear "2019" @default.
- W2969477586 type Work @default.
- W2969477586 sameAs 2969477586 @default.
- W2969477586 citedByCount "0" @default.
- W2969477586 crossrefType "journal-article" @default.
- W2969477586 hasAuthorship W2969477586A5016027668 @default.
- W2969477586 hasAuthorship W2969477586A5053193999 @default.
- W2969477586 hasAuthorship W2969477586A5083722360 @default.
- W2969477586 hasBestOaLocation W29694775861 @default.
- W2969477586 hasConcept C126322002 @default.
- W2969477586 hasConcept C141071460 @default.
- W2969477586 hasConcept C16005928 @default.
- W2969477586 hasConcept C197934379 @default.
- W2969477586 hasConcept C2776285725 @default.
- W2969477586 hasConcept C2776694085 @default.
- W2969477586 hasConcept C2777673923 @default.
- W2969477586 hasConcept C2777793932 @default.
- W2969477586 hasConcept C2780873365 @default.
- W2969477586 hasConcept C71924100 @default.
- W2969477586 hasConcept C90924648 @default.
- W2969477586 hasConceptScore W2969477586C126322002 @default.
- W2969477586 hasConceptScore W2969477586C141071460 @default.
- W2969477586 hasConceptScore W2969477586C16005928 @default.
- W2969477586 hasConceptScore W2969477586C197934379 @default.
- W2969477586 hasConceptScore W2969477586C2776285725 @default.
- W2969477586 hasConceptScore W2969477586C2776694085 @default.
- W2969477586 hasConceptScore W2969477586C2777673923 @default.
- W2969477586 hasConceptScore W2969477586C2777793932 @default.
- W2969477586 hasConceptScore W2969477586C2780873365 @default.
- W2969477586 hasConceptScore W2969477586C71924100 @default.
- W2969477586 hasConceptScore W2969477586C90924648 @default.
- W2969477586 hasIssue "9" @default.
- W2969477586 hasLocation W29694775861 @default.
- W2969477586 hasOpenAccess W2969477586 @default.
- W2969477586 hasPrimaryLocation W29694775861 @default.
- W2969477586 hasRelatedWork W1831466767 @default.
- W2969477586 hasRelatedWork W1994508586 @default.
- W2969477586 hasRelatedWork W2027614408 @default.
- W2969477586 hasRelatedWork W2036840410 @default.
- W2969477586 hasRelatedWork W2080436120 @default.
- W2969477586 hasRelatedWork W2109592716 @default.
- W2969477586 hasRelatedWork W2305922381 @default.
- W2969477586 hasRelatedWork W2572390839 @default.
- W2969477586 hasRelatedWork W2789590115 @default.
- W2969477586 hasRelatedWork W4210853480 @default.
- W2969477586 hasVolume "139" @default.
- W2969477586 isParatext "false" @default.
- W2969477586 isRetracted "false" @default.
- W2969477586 magId "2969477586" @default.
- W2969477586 workType "article" @default.